Zuojie Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zuojie Luo has a total of 266 co-authors. Here are the top co-authors by number of shared publications:
Haiyan Yang
Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University
17 shared publicationsYingfen Qin
Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University
16 shared publicationsXinghuan Liang
Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University
14 shared publicationsZhenxing Huang
Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University
14 shared publicationsLi Yan
Department of Endocrinology Zhongshan University Sun Yat‐sen Memorial Hospital Guangzhou China
12 shared publicationsQin Wan
The Affiliated Hospital of Southwest Medical University Luzhou China
12 shared publications
Latest Publications
- Open Access
- 21 May 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1769220
Therapeutic efficacy of glucocorticoids, ATP, and antithyroid drugs in acute thyrotoxic myopathy: evaluation using the acute thyrotoxic myopathy symptom score
Background: Acute thyrotoxic myopathy (ATM) is a relatively rare and severe complication of hyperthyroidism, mainly reported in individual cases and lacking standardized treatment protocols. Objective: This study evaluated the efficacy of glucocorticoids (GCs), adenosine triphosphate (ATP), and antithyroid drugs (ATDs) in treating ATM to guide clinical management. Methods: We retrospectively analyzed 42 ATM patients treated with GCs, ATP, and ATDs. The Acute Thyrotoxic Myopathy Symptom Score (ATMSS) was applied to evaluate efficacy at baseline (T0), day 7 (T7), and day 28 (T28) of treatment. Binary logistic regression was used to identify predictors of therapeutic efficacy, examining the impact of pre-treatment biochemical indicators and ATMSS on symptom relief (R) at T7 and complete remission (CR) at T28. Result: ATMSS demonstrated significant improvement at both T7 and T28 ( P < 0.001). R and CR rates differed among symptoms, with nasal reflux, dysphagia, and dyspnea showing markedly higher rates than dysarthria, gag reflex, and muscle weakness (T7: χ² = 30.89, T28: χ² = 36.71, both P < 0.001). Binary logistic regression analysis indicated that higher baseline dysarthria scores were associated with lower R rates at T7 ( OR = 0.216, 95% CI = 0.056–0.836, P = 0.027), while more severe muscle weakness at T7 predicted lower CR at T28 ( OR = 0.564, 95% CI = 0.323–0.984, P = 0.044). Conclusion: The combination of GCs, ATP, and ATDs effectively alleviated the ATMSS in the short (7day) and medium (28day) term. However, recovery rates differ among symptoms. Specifically, dysarthria at baseline and muscle weakness at T7 showed significant predictive value for treatment outcomes.
- 21 May 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1769220
Open AccessTherapeutic efficacy of glucocorticoids, ATP, and antithyroid drugs in acute thyrotoxic myopathy: evaluation using the acute thyrotoxic myopathy symptom score
Background: Acute thyrotoxic myopathy (ATM) is a relatively rare and severe complication of hyperthyroidism, mainly reported in individual cases and lacking standardized treatment protocols. Objective: This study evaluated the efficacy of glucocorticoids (GCs), adenosine triphosphate (ATP), and antithyroid drugs (ATDs) in treating ATM to guide clinical management. Methods: We retrospectively analyzed 42 ATM patients treated with GCs, ATP, and ATDs. The Acute Thyrotoxic Myopathy Symptom Score (ATMSS) was applied to evaluate efficacy at baseline (T0), day 7 (T7), and day 28 (T28) of treatment. Binary logistic regression was used to identify predictors of therapeutic efficacy, examining the impact of pre-treatment biochemical indicators and ATMSS on symptom relief (R) at T7 and complete remission (CR) at T28. Result: ATMSS demonstrated significant improvement at both T7 and T28 ( P < 0.001). R and CR rates differed among symptoms, with nasal reflux, dysphagia, and dyspnea showing markedly higher rates than dysarthria, gag reflex, and muscle weakness (T7: χ² = 30.89, T28: χ² = 36.71, both P < 0.001). Binary logistic regression analysis indicated that higher baseline dysarthria scores were associated with lower R rates at T7 ( OR = 0.216, 95% CI = 0.056–0.836, P = 0.027), while more severe muscle weakness at T7 predicted lower CR at T28 ( OR = 0.564, 95% CI = 0.323–0.984, P = 0.044). Conclusion: The combination of GCs, ATP, and ATDs effectively alleviated the ATMSS in the short (7day) and medium (28day) term. However, recovery rates differ among symptoms. Specifically, dysarthria at baseline and muscle weakness at T7 showed significant predictive value for treatment outcomes.
- Open Access
- 7 April 2026
- Published by Wiley in Journal of Diabetes
- Vol. 18 (4) , e70222
Association Between Socioeconomic Status and the Prevalence of Metabolic Diseases: A Nationwide Cross‐Sectional Study in China
Background: Metabolic diseases remain a fast‐growing global health burden. Besides other known factors, socioeconomic status (SES) has been recognized as a key determinant of metabolic health. This study aimed to investigate the association between SES and the prevalence of metabolic diseases in the Chinese population. Methods: We analyzed data from a nationwide community‐based cross‐sectional study in China. SES was derived to a composite score (range 0–3) using three indicators (educational attainment, living conditions, and marital status), with higher scores indicating better SES. Chronic diseases were diagnosed through biochemical testing and clinical assessments. Logistic regression models were applied to estimate associations between SES scores and metabolic diseases. Results: Among 201 532 participants, the lowest SES group had 87.1% higher odds of metabolic diseases than the highest SES group (odds ratio [OR] = 1.871, 95% confidence interval [CI]: 1.739, 2.016). One‐point decrease in SES score was associated with increased prevalence of hypertension (OR = 1.096, 95% CI: 1.080, 1.113) and obesity (OR = 1.112, 95% CI: 1.091, 1.134). In contrast, lower SES scores were linked to a reduced prevalence of dyslipidemia (OR = 0.931, 95% CI: 0.918, 0.945) and diabetes (OR = 0.974, 95% CI: 0.958, 0.990) after adjusting for covariates. We also observed that lower SES scores showed stronger associations with increased prevalence of obesity and hypertension in women but decreased risks of diabetes, dyslipidemia, and obesity in men. Conclusions: Lower SES was associated with a higher prevalence of hypertension and obesity but a lower prevalence of dyslipidemia and diabetes, with significant gender differences.
- 7 April 2026
- Published by Wiley in Journal of Diabetes
- Vol. 18 (4) , e70222
Open AccessAssociation Between Socioeconomic Status and the Prevalence of Metabolic Diseases: A Nationwide Cross‐Sectional Study in China
Background: Metabolic diseases remain a fast‐growing global health burden. Besides other known factors, socioeconomic status (SES) has been recognized as a key determinant of metabolic health. This study aimed to investigate the association between SES and the prevalence of metabolic diseases in the Chinese population. Methods: We analyzed data from a nationwide community‐based cross‐sectional study in China. SES was derived to a composite score (range 0–3) using three indicators (educational attainment, living conditions, and marital status), with higher scores indicating better SES. Chronic diseases were diagnosed through biochemical testing and clinical assessments. Logistic regression models were applied to estimate associations between SES scores and metabolic diseases. Results: Among 201 532 participants, the lowest SES group had 87.1% higher odds of metabolic diseases than the highest SES group (odds ratio [OR] = 1.871, 95% confidence interval [CI]: 1.739, 2.016). One‐point decrease in SES score was associated with increased prevalence of hypertension (OR = 1.096, 95% CI: 1.080, 1.113) and obesity (OR = 1.112, 95% CI: 1.091, 1.134). In contrast, lower SES scores were linked to a reduced prevalence of dyslipidemia (OR = 0.931, 95% CI: 0.918, 0.945) and diabetes (OR = 0.974, 95% CI: 0.958, 0.990) after adjusting for covariates. We also observed that lower SES scores showed stronger associations with increased prevalence of obesity and hypertension in women but decreased risks of diabetes, dyslipidemia, and obesity in men. Conclusions: Lower SES was associated with a higher prevalence of hypertension and obesity but a lower prevalence of dyslipidemia and diabetes, with significant gender differences.
- Open Access
- 28 February 2026
- Published by Elsevier in Immunology Letters
- Vol. 280, 107156
Vitamin D ameliorates NETosis and Th17/Treg imbalance in experimental autoimmune thyroiditis
- 28 February 2026
- Published by Elsevier in Immunology Letters
- Vol. 280, 107156
Open AccessVitamin D ameliorates NETosis and Th17/Treg imbalance in experimental autoimmune thyroiditis
- Open Access
- 12 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (50) , e46364
Thyroid storm complicated by metabolic encephalopathy in a young patient: A case report and literature review
Rationale: Metabolic encephalopathy is a rare but potentially devastating complication of thyroid storm. Its etiology is complex, clinical manifestations are diverse, there is no clear diagnostic criteria, so it is easy to lead to missed diagnosis, misdiagnosis, and mistreatment. We report a case of thyroid storm complicated by metabolic encephalopathy. Patient concerns: A 20-year-old male patient with a history of hyperthyroidism was admitted to the hospital because of limb twitching, foaming at the mouth and coma. The laboratory test results confirmed the diagnosis of thyroid storm. After treatment, the patient’s clinical symptoms gradually improved. Diagnosis: The diagnosis was thyroid crisis complicated with metabolic encephalopathy, sepsis, pneumonia, acute kidney damage, liver function impairment, and rhabdomyolysis. Interventions: The patient was given 100 mg hydrocortisone intravenously per 8 hours, propylthiouracil tablets of 250 mg q4h by nasal feeding, propranolol of 50 mg q4h by nasal feeding, piperacillin 5 g q8h intravenously, tigecycline 50 mg q12h (the first drug is 100 mg) intravenously, voriconazole 0.2 g q12h intravenously, and continuous kidney replacement therapy. Outcomes: The patient’s vital signs stabilized, his consciousness level improved, and after being taken off the ventilator, he was transferred to the Department of Traditional Chinese Medicine, where he received Chinese medicine and rehabilitation treatment, and was discharged from the hospital after his condition improved. Lessons: Thyroid storm complicated by metabolic encephalopathy requires early diagnosis and treatment, and the neurological function damage caused by it is usually reversible.
- 12 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (50) , e46364
Open AccessThyroid storm complicated by metabolic encephalopathy in a young patient: A case report and literature review
Rationale: Metabolic encephalopathy is a rare but potentially devastating complication of thyroid storm. Its etiology is complex, clinical manifestations are diverse, there is no clear diagnostic criteria, so it is easy to lead to missed diagnosis, misdiagnosis, and mistreatment. We report a case of thyroid storm complicated by metabolic encephalopathy. Patient concerns: A 20-year-old male patient with a history of hyperthyroidism was admitted to the hospital because of limb twitching, foaming at the mouth and coma. The laboratory test results confirmed the diagnosis of thyroid storm. After treatment, the patient’s clinical symptoms gradually improved. Diagnosis: The diagnosis was thyroid crisis complicated with metabolic encephalopathy, sepsis, pneumonia, acute kidney damage, liver function impairment, and rhabdomyolysis. Interventions: The patient was given 100 mg hydrocortisone intravenously per 8 hours, propylthiouracil tablets of 250 mg q4h by nasal feeding, propranolol of 50 mg q4h by nasal feeding, piperacillin 5 g q8h intravenously, tigecycline 50 mg q12h (the first drug is 100 mg) intravenously, voriconazole 0.2 g q12h intravenously, and continuous kidney replacement therapy. Outcomes: The patient’s vital signs stabilized, his consciousness level improved, and after being taken off the ventilator, he was transferred to the Department of Traditional Chinese Medicine, where he received Chinese medicine and rehabilitation treatment, and was discharged from the hospital after his condition improved. Lessons: Thyroid storm complicated by metabolic encephalopathy requires early diagnosis and treatment, and the neurological function damage caused by it is usually reversible.
- Open Access
- 10 April 2025
- Published by Springer Nature in Research Square
GAD65 antibody-associated autoimmune encephalitis with autoimmune polyendocrine gland syndrome type II: case report and literature review
Purpose: This report presents a case of autoimmune encephalitis associated with glutamic acid decarboxylase 65 (GAD65) antibodies, complicated by autoimmune polyendocrine syndrome type II (APS-II), aiming to elucidate the clinical spectrum and disease progression, thereby enhancing clinical comprehension of this condition. Methods: We analyzed the case data of a patient with autoimmune encephalitis associated with GAD65 antibodies, complicated by APS-II, and reviewed the pertinent literature. Results: The patient, a 29-year-old female, exhibited a subacute onset of the illness, manifesting as recurrent seizures. She tested positive for GAD65 antibodies in serum and cerebrospinal fluid, exhibited elevated fasting and 2-hour postprandial glucose levels, and had an elevated HbA1c. With a prior diagnosis of hyperthyroidism, she was diagnosed with GAD65-associated autoimmune encephalitis complicated by APS-II and responded well to hormonal anti-inflammatory and symptomatic treatment. Conclusions: Autoimmune encephalitis associated with GAD65 antibodies, complicated by APS-II, is a rare and complex clinical entity, prone to misdiagnosis. The prompt initiation of immunotherapy can markedly improve patient prognosis.
- 10 April 2025
- Published by Springer Nature in Research Square
Open AccessGAD65 antibody-associated autoimmune encephalitis with autoimmune polyendocrine gland syndrome type II: case report and literature review
Purpose: This report presents a case of autoimmune encephalitis associated with glutamic acid decarboxylase 65 (GAD65) antibodies, complicated by autoimmune polyendocrine syndrome type II (APS-II), aiming to elucidate the clinical spectrum and disease progression, thereby enhancing clinical comprehension of this condition. Methods: We analyzed the case data of a patient with autoimmune encephalitis associated with GAD65 antibodies, complicated by APS-II, and reviewed the pertinent literature. Results: The patient, a 29-year-old female, exhibited a subacute onset of the illness, manifesting as recurrent seizures. She tested positive for GAD65 antibodies in serum and cerebrospinal fluid, exhibited elevated fasting and 2-hour postprandial glucose levels, and had an elevated HbA1c. With a prior diagnosis of hyperthyroidism, she was diagnosed with GAD65-associated autoimmune encephalitis complicated by APS-II and responded well to hormonal anti-inflammatory and symptomatic treatment. Conclusions: Autoimmune encephalitis associated with GAD65 antibodies, complicated by APS-II, is a rare and complex clinical entity, prone to misdiagnosis. The prompt initiation of immunotherapy can markedly improve patient prognosis.
- Open Access
- 12 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 8467
Elevated serum CD40 as a potential biomarker for the differential diagnosis of acute thyrotoxic myopathy
Acute thyrotoxic myopathy (ATM) is a rare yet severe complication of thyrotoxicosis that affects the central nervous system and is associated with a high mortality rate if not diagnosed and treated promptly. Currently, the diagnosis of ATM primarily relies on clinical manifestations, and there is a lack of specific serological markers to support the diagnostic process. This study aimed to investigate the differences in serum CD40 levels between patients with acute thyrotoxic myopathy (ATM), those with Graves' disease, and healthy controls, and to evaluate its potential as a diagnostic biomarker for differentiating ATM. Additionally, the study examined the correlation between serum CD40 levels and various parameters, including the ATM symptom score (ATMSS), FT3, FT4, TSH, TGAb, TRAb, and TPOAb. This retrospective cross-sectional study included 17 patients with ATM, 17 patients with Graves' disease, and 17 healthy controls, all recruited from the First Affiliated Hospital of Guangxi Medical University between January 2022 and August 2024. Clinical evaluations, serum thyroid hormone and related antibody testing, and CD40 level measurements were conducted. The predictive value of CD40, FT3, FT4, TSH, TGAb, TRAb, and ATMSS for ATM was assessed using receiver operating characteristic (ROC) curve analysis. Spearman correlation analysis was performed to explore the relationship between CD40 levels and ATMSS, FT3, FT4, TSH, TGAb, TRAb, and TPOAb. Serum levels of CD40[259.17(227.50,378.03)vs.190.71(174.08,198.96)vs. 166.98(142.94,175.90)], FT3[28.34(17.13,37.65) vs. 8.82(6.36,21.00) vs. 5.02(3.93,5.45)], and FT4 [67.58(37.53,77.23)vs.27.03(15.96,47.05)vs.16.82(13.59,17.90)]in ATM patients were significantly higher than those in Graves' disease patients and the control group, with statistically significant differences (P < 0.01). ROC analysis demonstrated that CD40 has high predictive value for distinguishing between GD and ATM, with an area under the curve (AUC) of 0.99, and both sensitivity and specificity of 94.1%. Correlation analysis revealed a positive correlation between CD40 and the ATM symptom score (ATMSS) (r = 0.72, P < 0.01). Positive correlations were also observed between CD40 and FT3 (r = 0.53, P < 0.01) and FT4 (r = 0.56, P < 0.01). TSH showed a negative correlation trend with CD40 (r = -0.21, P = 0.23), but this difference was not statistically significant. No significant correlations were found between CD40 and TGAb (r = 0.10, P = 0.59), TRAb (r = 0.26, P = 0.13), or TPOAb (r = 0.06, P = 0.72). Elevated serum CD40 levels are associated with the severity of ATM symptoms and may serve as a potential biomarker for ATM. The role of CD40 as an adjunct in the early diagnosis of ATM holds clinical significance, offering new insights into the differential diagnosis and treatment of ATM.
- 12 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 8467
Open AccessElevated serum CD40 as a potential biomarker for the differential diagnosis of acute thyrotoxic myopathy
Acute thyrotoxic myopathy (ATM) is a rare yet severe complication of thyrotoxicosis that affects the central nervous system and is associated with a high mortality rate if not diagnosed and treated promptly. Currently, the diagnosis of ATM primarily relies on clinical manifestations, and there is a lack of specific serological markers to support the diagnostic process. This study aimed to investigate the differences in serum CD40 levels between patients with acute thyrotoxic myopathy (ATM), those with Graves' disease, and healthy controls, and to evaluate its potential as a diagnostic biomarker for differentiating ATM. Additionally, the study examined the correlation between serum CD40 levels and various parameters, including the ATM symptom score (ATMSS), FT3, FT4, TSH, TGAb, TRAb, and TPOAb. This retrospective cross-sectional study included 17 patients with ATM, 17 patients with Graves' disease, and 17 healthy controls, all recruited from the First Affiliated Hospital of Guangxi Medical University between January 2022 and August 2024. Clinical evaluations, serum thyroid hormone and related antibody testing, and CD40 level measurements were conducted. The predictive value of CD40, FT3, FT4, TSH, TGAb, TRAb, and ATMSS for ATM was assessed using receiver operating characteristic (ROC) curve analysis. Spearman correlation analysis was performed to explore the relationship between CD40 levels and ATMSS, FT3, FT4, TSH, TGAb, TRAb, and TPOAb. Serum levels of CD40[259.17(227.50,378.03)vs.190.71(174.08,198.96)vs. 166.98(142.94,175.90)], FT3[28.34(17.13,37.65) vs. 8.82(6.36,21.00) vs. 5.02(3.93,5.45)], and FT4 [67.58(37.53,77.23)vs.27.03(15.96,47.05)vs.16.82(13.59,17.90)]in ATM patients were significantly higher than those in Graves' disease patients and the control group, with statistically significant differences (P < 0.01). ROC analysis demonstrated that CD40 has high predictive value for distinguishing between GD and ATM, with an area under the curve (AUC) of 0.99, and both sensitivity and specificity of 94.1%. Correlation analysis revealed a positive correlation between CD40 and the ATM symptom score (ATMSS) (r = 0.72, P < 0.01). Positive correlations were also observed between CD40 and FT3 (r = 0.53, P < 0.01) and FT4 (r = 0.56, P < 0.01). TSH showed a negative correlation trend with CD40 (r = -0.21, P = 0.23), but this difference was not statistically significant. No significant correlations were found between CD40 and TGAb (r = 0.10, P = 0.59), TRAb (r = 0.26, P = 0.13), or TPOAb (r = 0.06, P = 0.72). Elevated serum CD40 levels are associated with the severity of ATM symptoms and may serve as a potential biomarker for ATM. The role of CD40 as an adjunct in the early diagnosis of ATM holds clinical significance, offering new insights into the differential diagnosis and treatment of ATM.
- Open Access
- 1 January 2025
- Published by Wiley in International Journal of Endocrinology
- Vol. 2025 (1)
Diagnostic Value and Clinical Validation of Acute Thyrotoxic Myopathy Symptom Score in Acute Thyrotoxic Myopathy
Objectives: Acute thyrotoxic myopathy (ATM) is characterized by bulbar paralysis and limb myasthenia on the basis of hyperthyroidism, which can cause respiratory failure, coma and death. However, the diagnosis of ATM is challenging. The purpose of this study was to develop a symptom rating scale named Acute Thyrotoxic Myopathy Symptom Score (ATMSS) to assist in the early diagnosis of ATM in clinical practice. Methods: (1) The ATM reference cohort was constructed by searching for patients diagnosed with ATM or thyrotoxic bulbar palsy in the PubMed, Embase and Web of Science databases (ATM cohort); (2) the ATMSS was formulated based on the ATM cohort after multidisciplinary discussion; and (3) 38 patients with ATM and 40 patients with Graves’ disease (GD) were enrolled in the study; (4) receiver operating characteristic (ROC) curve analysis was applied to appraisal diagnostic value of the ATMSS for differentiating patients with ATM from patients with GD; (5) we also evaluated the correlation between ATMSS and age of onset, sex, thyroid function and thyroid‐related antibody. Results: The ATMSS showed better diagnostic value at an optimal cut‐off value of 4.5 [area under the curve (AUC) = 0.978; 95% confidence interval (CI) = 0.949–1; p < 0.0001; sensitivity = 94.7%; specificity = 95%]. The ATMSS was positively correlated with free triiodothyronine (FT 3 ) [Spearman correlation coefficient ( r s ) = 0.409, p < 0.001], free thyroxine (FT 4 ) ( r s = 0.486, p < 0.001) and thyrotrophin receptor antibody (TRAb) ( r s = 0.332, p = 0.003), but negative correlation with the age of onset ( r s = −0.349, p = 0.002). Conclusions: We developed a symptom rating scale named the ATMSS, which is effective in diagnosing ATM from GD, and ATMSS is positively correlated with thyroid function and TRAb, but negative correlation with the age of onset. ATMSS can be used as an additional tool for diagnosing ATM.
- 1 January 2025
- Published by Wiley in International Journal of Endocrinology
- Vol. 2025 (1)
Open AccessDiagnostic Value and Clinical Validation of Acute Thyrotoxic Myopathy Symptom Score in Acute Thyrotoxic Myopathy
Objectives: Acute thyrotoxic myopathy (ATM) is characterized by bulbar paralysis and limb myasthenia on the basis of hyperthyroidism, which can cause respiratory failure, coma and death. However, the diagnosis of ATM is challenging. The purpose of this study was to develop a symptom rating scale named Acute Thyrotoxic Myopathy Symptom Score (ATMSS) to assist in the early diagnosis of ATM in clinical practice. Methods: (1) The ATM reference cohort was constructed by searching for patients diagnosed with ATM or thyrotoxic bulbar palsy in the PubMed, Embase and Web of Science databases (ATM cohort); (2) the ATMSS was formulated based on the ATM cohort after multidisciplinary discussion; and (3) 38 patients with ATM and 40 patients with Graves’ disease (GD) were enrolled in the study; (4) receiver operating characteristic (ROC) curve analysis was applied to appraisal diagnostic value of the ATMSS for differentiating patients with ATM from patients with GD; (5) we also evaluated the correlation between ATMSS and age of onset, sex, thyroid function and thyroid‐related antibody. Results: The ATMSS showed better diagnostic value at an optimal cut‐off value of 4.5 [area under the curve (AUC) = 0.978; 95% confidence interval (CI) = 0.949–1; p < 0.0001; sensitivity = 94.7%; specificity = 95%]. The ATMSS was positively correlated with free triiodothyronine (FT 3 ) [Spearman correlation coefficient ( r s ) = 0.409, p < 0.001], free thyroxine (FT 4 ) ( r s = 0.486, p < 0.001) and thyrotrophin receptor antibody (TRAb) ( r s = 0.332, p = 0.003), but negative correlation with the age of onset ( r s = −0.349, p = 0.002). Conclusions: We developed a symptom rating scale named the ATMSS, which is effective in diagnosing ATM from GD, and ATMSS is positively correlated with thyroid function and TRAb, but negative correlation with the age of onset. ATMSS can be used as an additional tool for diagnosing ATM.
- Open Access
- 28 November 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16 (1) , 1-17
Identification of metabolic reprogramming-related genes as potential diagnostic biomarkers for diabetic nephropathy based on bioinformatics
Diabetic nephropathy (DN) is a serious complication of diabetes mellitus, marked by progressive renal damage. Recent evidence indicates that metabolic reprogramming is crucial to DN pathogenesis, yet its underlying mechanisms are not well understood. This study aimed to examine how metabolic reprogramming-related genes (MRRGs) are differentially expressed and to explore their potential mechanisms in the development of DN. We analyzed the datasets GSE30528 and GSE96804 from the Gene Expression Omnibus (GEO), comprising 50 DN samples and 33 controls. MRRGs were sourced from GeneCards and PubMed. Data preprocessing included batch effect correction using the R package sva, followed by normalization and differential expression analysis with limma (|logFC|> 0.5, adj.p < 0.05). Functional enrichment analyses (GO, KEGG, GSEA) were performed using clusterProfiler. Protein–protein interaction (PPI) networks were constructed via STRING, identifying hub genes through CytoHubba. Regulatory networks (mRNA-TF, mRNA-miRNA) were derived from ChIPBase and StarBase. Validation of hub genes and ROC analysis assessed diagnostic performance. ssGSEA quantified immune cell infiltration. Our analysis identified 708 differentially expressed genes (DEGs), including 119 metabolic reprogramming-related DEGs (MRRDEGs). Enrichment analyses revealed significant roles for MRRDEGs in processes such as wound healing and pathways like MAPK signaling. The PPI network identified nine hub genes: FN1, CD44, KDR, EGF, HSPG2, HGF, FGF9, IGF1, and ALB, which exhibited high diagnostic accuracy (AUC 0.7 to 0.9). Notably, FN1 and CD44 showed significant association with renal fibrosis and could serve as potential biomarkers for early diagnosis and therapeutic targets in DN. Immune infiltration analysis showed notable differences in immune cell composition between DN and control samples. This study identifies hub genes such as FN1 and CD44, with potential diagnostic value in DN. It also reveals immune cell infiltration differences between DN patients and controls, offering insights into disease progression and potential therapeutic targets.
- 28 November 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16 (1) , 1-17
Open AccessIdentification of metabolic reprogramming-related genes as potential diagnostic biomarkers for diabetic nephropathy based on bioinformatics
Diabetic nephropathy (DN) is a serious complication of diabetes mellitus, marked by progressive renal damage. Recent evidence indicates that metabolic reprogramming is crucial to DN pathogenesis, yet its underlying mechanisms are not well understood. This study aimed to examine how metabolic reprogramming-related genes (MRRGs) are differentially expressed and to explore their potential mechanisms in the development of DN. We analyzed the datasets GSE30528 and GSE96804 from the Gene Expression Omnibus (GEO), comprising 50 DN samples and 33 controls. MRRGs were sourced from GeneCards and PubMed. Data preprocessing included batch effect correction using the R package sva, followed by normalization and differential expression analysis with limma (|logFC|> 0.5, adj.p < 0.05). Functional enrichment analyses (GO, KEGG, GSEA) were performed using clusterProfiler. Protein–protein interaction (PPI) networks were constructed via STRING, identifying hub genes through CytoHubba. Regulatory networks (mRNA-TF, mRNA-miRNA) were derived from ChIPBase and StarBase. Validation of hub genes and ROC analysis assessed diagnostic performance. ssGSEA quantified immune cell infiltration. Our analysis identified 708 differentially expressed genes (DEGs), including 119 metabolic reprogramming-related DEGs (MRRDEGs). Enrichment analyses revealed significant roles for MRRDEGs in processes such as wound healing and pathways like MAPK signaling. The PPI network identified nine hub genes: FN1, CD44, KDR, EGF, HSPG2, HGF, FGF9, IGF1, and ALB, which exhibited high diagnostic accuracy (AUC 0.7 to 0.9). Notably, FN1 and CD44 showed significant association with renal fibrosis and could serve as potential biomarkers for early diagnosis and therapeutic targets in DN. Immune infiltration analysis showed notable differences in immune cell composition between DN and control samples. This study identifies hub genes such as FN1 and CD44, with potential diagnostic value in DN. It also reveals immune cell infiltration differences between DN patients and controls, offering insights into disease progression and potential therapeutic targets.
- 1 November 2024
- Vol. 54 (6) , 810-819
Se-methylselenocysteine Inhibits Migration and Glycolysis in Anaplastic Thyroid Carcinoma Cells via the ERK1/2 Signaling Pathway in vitro.
The aim of the present study was to determine the effects of selenium-methylselenocysteine (MSC) on the viability, migration, and glycolysis of human ATC cell lines 8305 and BHT101 in vitro. Cells were treated with MSC and viability was determined using the Cell Counting Kit 8 assay. The migratory ability of cells was detected using a Transwell migration assay, and the expression levels of proteins involved in the ERK1/2, JNK, and p38 signaling pathways were measured by western blotting. Glycolysis was investigated by determining glucose consumption, lactate production, and protein levels of key glycolytic enzymes (glucose transporter 1, hexokinase 2, and lactate dehydrogenase A). MSC inhibited the viability, migration, and glycolysis of ATC cells. Phosphorylated (p)-ERK1/2 expression decreased with increasing MSC concentration; however, p-JNK and p-p38 levels were unaffected in cell lines 8305C and BHT101. Epidermal growth factor induced activation of ERK1/2 and impaired the inhibitory effect of MSC on ATC cell viability, migration, and glycolysis. These findings indicated that MSC inhibited the viability, migration, and glycolysis of ATC cells via the ERK1/2 signaling pathway, suggesting that MSC may represent a novel therapeutic agent for ATC.
- 1 November 2024
- Vol. 54 (6) , 810-819
Se-methylselenocysteine Inhibits Migration and Glycolysis in Anaplastic Thyroid Carcinoma Cells via the ERK1/2 Signaling Pathway in vitro.
The aim of the present study was to determine the effects of selenium-methylselenocysteine (MSC) on the viability, migration, and glycolysis of human ATC cell lines 8305 and BHT101 in vitro. Cells were treated with MSC and viability was determined using the Cell Counting Kit 8 assay. The migratory ability of cells was detected using a Transwell migration assay, and the expression levels of proteins involved in the ERK1/2, JNK, and p38 signaling pathways were measured by western blotting. Glycolysis was investigated by determining glucose consumption, lactate production, and protein levels of key glycolytic enzymes (glucose transporter 1, hexokinase 2, and lactate dehydrogenase A). MSC inhibited the viability, migration, and glycolysis of ATC cells. Phosphorylated (p)-ERK1/2 expression decreased with increasing MSC concentration; however, p-JNK and p-p38 levels were unaffected in cell lines 8305C and BHT101. Epidermal growth factor induced activation of ERK1/2 and impaired the inhibitory effect of MSC on ATC cell viability, migration, and glycolysis. These findings indicated that MSC inhibited the viability, migration, and glycolysis of ATC cells via the ERK1/2 signaling pathway, suggesting that MSC may represent a novel therapeutic agent for ATC.
- Open Access
- 18 October 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (42) , e40128
Exploring the mechanism of comorbidity in patients with T1DM and COVID-19: Integrating bioinformatics and Mendelian randomization methods
During the coronavirus disease 2019 (COVID-19) pandemic, the incidence of type 1 diabetes mellitus (T1DM) has increased. Additionally, evidence suggests that individuals with diabetes mellitus may have increased susceptibility to severe acute respiratory syndrome coronavirus 2 infection. However, the specific causal relationships and interaction mechanisms between T1DM and COVID-19 remain unclear. This study aims to investigate the causal relationship between T1DM and COVID-19, utilizing differential gene expression and Mendelian randomization analyses. Differentially expressed gene sets from datasets GSE156035 and GSE171110 were intersected to identify shared genes, analyzed for functional enrichment. Mendelian randomization models were employed to assess causal effects, revealing no direct causal link between T1DM and COVID-19 in the European population (P > .05). Notably, DNA replication and sister chromatid cohesion 1 (DSCC1) showed negative causal associations with both diseases (T1DM: OR = 0.943, 95% CI: 0.898–0.991, P = .020; COVID-19: OR = 0.919, 95% CI: 0.882–0.958, P < .001), suggesting a protective effect against their comorbidity. This genetic evidence highlights DSCC1 as a potential target for monitoring and managing the co-occurrence of T1DM and COVID-19.
- 18 October 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (42) , e40128
Open AccessExploring the mechanism of comorbidity in patients with T1DM and COVID-19: Integrating bioinformatics and Mendelian randomization methods
During the coronavirus disease 2019 (COVID-19) pandemic, the incidence of type 1 diabetes mellitus (T1DM) has increased. Additionally, evidence suggests that individuals with diabetes mellitus may have increased susceptibility to severe acute respiratory syndrome coronavirus 2 infection. However, the specific causal relationships and interaction mechanisms between T1DM and COVID-19 remain unclear. This study aims to investigate the causal relationship between T1DM and COVID-19, utilizing differential gene expression and Mendelian randomization analyses. Differentially expressed gene sets from datasets GSE156035 and GSE171110 were intersected to identify shared genes, analyzed for functional enrichment. Mendelian randomization models were employed to assess causal effects, revealing no direct causal link between T1DM and COVID-19 in the European population (P > .05). Notably, DNA replication and sister chromatid cohesion 1 (DSCC1) showed negative causal associations with both diseases (T1DM: OR = 0.943, 95% CI: 0.898–0.991, P = .020; COVID-19: OR = 0.919, 95% CI: 0.882–0.958, P < .001), suggesting a protective effect against their comorbidity. This genetic evidence highlights DSCC1 as a potential target for monitoring and managing the co-occurrence of T1DM and COVID-19.